 |
Prospector
Profile
07.1166
|
| |
| Bionovo, Inc. |
NAICS |
541710 |
| 5858 Horton Street, Suite 375
Emeryville, CA 94608 |
Description |
Pharmaceuticals Research |
| (510) 601-2000 |
Employees |
19 |
| http://www.bionovo.com/ |
Revenue |
(mil) |
0.0150 |
| |
Income |
(mil) |
-5.6170 |
| |
Assets |
(mil) |
4.9720 |
| |
Liability |
(mil) |
1.4750 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Bionovo, Inc. reported a net loss of $2,656,348 for the three months ended June 30, 2007, more than double the net loss reported during the same period a year ago of $1,227,001. The Company also used cash for operating activities of $4,684,462 for the quarter ended June 30, 2007, much higher than the $1,755,568 used during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of $15,850,323 in its June 30, 2006 balance sheet.
|
| |
|
Intellectual Property:
The Company has filed four patent applications with the United States Patent & Trademark Office and one patent application with the Taiwan Intellectual Property Office related to its drug candidates. The Company's competitive position is also dependent upon unpatented trade secrets. [SEC Filing 10-KSB 03-14-07]
|
| |
|
Description:
The Company engages in the discovery and development of drugs in the areas of cancer and women's health primarily in the United States.
|
| |
|
Officers:
Isaac Cohen (Chair, Pres., CEO & Chief Scientific Officer); James P. Stapleton (CFO); Mary Tagliaferri (VP, Sec., Treas. & Dir.); David Naveh (Dir.); Michael Vanderhoof (Dir.); Brooks Corbin (Dir.); Frances W. Preston (Dir.)
|
| |
|
Auditor:
PMB Helin Donovan LLP
|
| |
|
Securities:
Common Stock-Symbol BNVI; NasdaqCM;
65,443,934 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
